Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? by Wehner, Gregory J. et al.
 
 
 
 
 
 
Wehner, G. J. et al. (2020) Routinely reported ejection fraction and mortality in clinical 
practice: where does the nadir of risk lie? European Heart Journal, 41(12), pp. 1249-
1257. (doi: 10.1093/eurheartj/ehz550)  
 
There may be differences between this version and the published version. You are  
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/190805/ 
      
 
 
 
 
 
Deposited on 23 July 2019 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Title: Routinely Reported Ejection Fraction and Mortality in Clinical Practice: Where Does the 
Nadir of Risk Lie? 
Authors: Gregory J. Wehner, PhDa; Linyuan Jing, PhDb,c; Christopher M. Haggerty, PhDb,c; 
Jonathan D. Suever, PhDb,c; Joseph B. Leader, BAc; Dustin N. Hartzel, BSc; H. Lester Kirchner, 
PhDc; Joseph N. A. Manusc, BS; Nick James;d Zina Ayar;e Patrick Gladding, MD, PhDd; 
Christopher W. Good, DOf; John G.F. Cleland, MD, PhDg; Brandon K. Fornwalt, MD, PhDb,c,f,h* 
aDepartment of Biomedical Engineering, University of Kentucky, Lexington, KY, United States 
bDepartment of Imaging Science and Innovation, Geisinger, Danville, PA, United States 
cBiomedical and Translational Informatics Institute, Geisinger, Danville, PA, United States 
dDepartment of Cardiology, Waitemata District Health Board, Auckland, New Zealand 
eClinical Informatics Service, Waitemata District Health Board, Auckland, New Zealand 
fHeart Institute, Geisinger, Danville, PA, United States 
gRobertson Centre for Biostatistics and Clinical Trials, University of Glasgow and National Heart & Lung 
Institute, Imperial College London, London, UK  
hDepartment of Radiology, Geisinger, Danville, PA, United States 
 
Emails: Wehner GJ, wehnergj@gmail.com; Jing L, jinglinyuan2008@gmail.com; Haggerty CM, 
chaggerty3@gatech.edu; Suever JD, suever@gmail.com; Leader JB, jbleader@geisinger.edu; Hartzel DN, 
dnhartzel@geisinger.edu; Kirchner HL, hlkirchner@geisinger.edu; Manus JNA, jamanus@geisinger.edu; James N, 
njam033@aucklanduni.ac.nz; Ayar Z, Zina.ayar@waitematadhb.govt.nz; Gladding P, patrickg@theranosticslab.com; 
Good CW, cwgood1@geisinger.edu; Cleland JGF, j.cleland@imperial.ac.uk; Fornwalt BK, bkf@gatech.edu 
 
*Address for Correspondence 
Brandon K. Fornwalt, MD, PhD 
100 North Academy Avenue 
Danville PA, 17822-4400 
Email: bkf@gatech.edu 
Phone: 570-214-5478 
Fax: 570-214-9451 
 
Conflicts of Interest: None declared 
  
2 
 
ABSTRACT 
Aims: We investigated the relationship between clinically-assessed left ventricular ejection 
fraction (LVEF) and survival in a large, heterogeneous clinical cohort. 
Methods and Results: Physician-reported LVEF on 403,977 echocardiograms from 203,135 
patients were linked to all-cause mortality using electronic health records (1998–2018) from a 
United States (US) regional healthcare system. Cox Proportional Hazards Regression was used 
for analyses while adjusting for many patient characteristics including age, sex, and relevant 
comorbidities. A dataset including 45,531 echocardiograms and 35,976 patients from New 
Zealand was used to provide independent validation of analyses. During follow-up of the US 
cohort, 46,258 (23%) patients who had undergone 108,578 (27%) echocardiograms died. Overall, 
adjusted hazard ratios (HR) for mortality showed a u-shaped relationship for LVEF with a nadir of 
risk at an LVEF of 60-65%, a HR of 1.71 (95% CI, 1.64-1.77) when ≥70% and a HR of 1.73 
(95% CI, 1.66-1.80) at LVEF of 35-40%. Similar relationships with a nadir at 60-65% were 
observed in the validation dataset as well as for each age-group and both sexes. The results were 
similar after further adjustments for conditions associated with an elevated LVEF, including mitral 
regurgitation, increased wall thickness, and anemia and when restricted to patients reported to 
have heart failure at the time of the echocardiogram. 
Conclusion: Deviation of LVEF from 60-65% is associated with poorer survival regardless of 
age, sex or other relevant comorbidities such as heart failure. These results may herald the 
recognition of a new phenotype characterized by supra-normal LVEF. 
Keywords: Ejection fraction, Cardiac function, Survival, Mortality, Clinical practice 
  
3 
 
INTRODUCTION 
In patients with known or suspected heart disease, left ventricular ejection fraction (LVEF) is the 
most commonly used metric for quantifying ventricular function. Echocardiograms are requested 
for a broad population, extending from healthy patients with benign symptoms to those with 
severe heart failure. In 2011 alone, seven million echocardiograms were done on one of every 
five of US Medicare beneficiaries.(1) 
Despite widespread reporting of LVEF, the relationship between clinically-assessed LVEF and 
survival has never been well-defined in a large, clinical-practice population. Studies have focused 
on patients with heart failure,(2–7) have studied only a specific range (LVEF<40%) or used a 
crude dichotomization (LVEF above and below 50%),(2,7–12) and/or had only a modest sample 
size.(4,5,8,9)  The largest single cohort published had 8,399 patients, all with an LVEF ≤40%(6), 
and the largest meta-analysis of trials and registries had 41,972 patients, all of whom had heart 
failure.(13) Furthermore, patients in clinical trials may not be representative of clinical practice, 
and measurement of LVEF for research may differ, either because more time, effort and expertise 
is applied or because the estimate is biased by a desire to enroll patients in a study where LVEF 
is an inclusion criterion.(14,15) Assessment of LVEF in clinical practice, which is the 
measurement used to guide management, may be very different from that measured in a trial.  
We hypothesized that analysis of a large clinical dataset would provide a new understanding of 
the relationship between clinically-assessed LVEF and survival. We tested this hypothesis using 
data from a regional health system to capture the broad population of patients that undergo 
echocardiography. 
 
METHODS 
Study Design 
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All echocardiograms with physician-reported LVEF measured at rest were identified within 
Geisinger health records (1998–2018). Geisinger is a regional healthcare system in Pennsylvania 
with a catchment population of 3.5 million. Records were required to have the date of death or 
last living encounter and age, sex, height, and weight. Problem lists from clinics and 
hospitalizations were mapped to International Classification of Disease, Tenth Revision (ICD-10) 
codes, which were reviewed for the following diagnoses at the time of echocardiography: previous 
myocardial infarction, hypertension, diabetes mellitus, atrial fibrillation or flutter, congenital heart 
or great vessel defect, chronic kidney disease, and heart failure (Table S1). Indications for 
echocardiography and smoking history were obtained from structured data-fields. The use of 
angiotensin converting-enzyme inhibitors or angiotensin-II receptor blockers, evidence-based 
beta-blockers, loop diuretics, mineralocorticoid receptor antagonists, and digoxin were 
determined within 3 months of the echocardiogram. The use of inotropic agents was determined 
within one day of the echocardiogram. 
Similar echocardiographic data were gathered from the Waitemata District Health Board, the 
largest district health provider in New Zealand. This retrospective study complies with the 
Declaration of Helsinki, was approved by the Institutional Review Board, and was performed with 
a waiver of consent. 
LVEF Reporting 
Many (74%) of the LVEFs were reported as a range either 4% or 5% in width (e.g. 40-44%, 55-
60%). Therefore, all LVEFs were categorized into intervals 5% in width and inclusive of the lower 
threshold. The lowest and highest intervals were <20% and ≥70%, respectively. In addition to 
ranges, LVEF was reported as a single number or an inequality (e.g. <20%). A small number of 
reports with indeterminate inequalities were classified in the adjacent interval (e.g. <30% was 
categorized as 25-30%). Overall, 59% of the LVEF values were described as qualitative; 7% were 
derived from the bi-plane technique; 0.5% were derived from a 3D-volume technique; 0.4% were 
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derived from a single-plane technique. The remaining 33% of LVEFs did not include a description 
of their derivation. 
End Point 
The end point was death, which was recorded in the health system when possible and otherwise 
checked at least monthly against national databases: the Social Security Death Index (SSDI) for 
Geisinger patients and Statistics New Zealand (Tatauranga Aotearoa) for the validation dataset.  
For Geisinger patients, the date of last living encounter within a Geisinger facility was used for 
censoring. For New Zealand patients, mortality was censored on January 1, 2018. Previous 
studies of the SSDI demonstrated that 95% of deceased patients were confirmed deceased in 
the SSDI.(16) Under the provisions of the New Zealand Births, Deaths, Marriages, and 
Relationships Registration Act 1995, every death occurring in New Zealand must be registered. 
Subgroup Analyses 
Subgroup analyses investigated features potentially associated with pathologically elevated 
LVEF, such as heart rate, blood pressure, body temperature, increased wall thickness, decreased 
left ventricular volumes, mitral regurgitation (at least moderate), anemia (hemoglobin < 10 g/dL 
within 31 days of echocardiography) and hyperthyroidism (TSH < 0.10 mIU/L within 31 days of 
echocardiography). These subgroup analyses only included echocardiograms for which 
measurements of wall thickness, left ventricular volumes, and the severity or absence of mitral 
regurgitation were reported. For the subgroup of patients with heart failure, NT-proBNP was 
queried either during inpatient admission or within 6 months of echocardiography. 
Statistical Methods 
Follow-up time was reported using the reverse Kaplan-Meier method.(17) Cox Proportional 
Hazards Regression was used to model time-to-mortality based on LVEF and fixed baseline 
confounders including age, sex, height, body mass index (BMI), smoking history and 
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comorbidities. Analyses from New Zealand were not adjusted for confounders because the 
confounder data were incomplete. For the primary analysis, all echocardiograms were included 
such that patients contributed all echocardiograms from different points in their lives. Those 
echocardiograms were treated as independent observations with the exception that clustering 
was performed around each patient to account for possible correlation of observations from a 
single patient. Robust variance estimation was performed. One sensitivity analysis included only 
the first echocardiogram from each patient. Another sensitivity analysis excluded 
echocardiograms with indeterminate LVEF as well as those performed on patients less than 18 
years of age or with congenital heart or great vessel defects. Another sensitivity analysis allowed 
the interaction of exam setting (either inpatient or outpatient) with LVEF. To investigate the impact 
of serious acute illness, another sensitivity analysis excluded echocardiograms for which the time 
until either death or last encounter was less than 90 days.  Additional analyses included 
interactions between LVEF and age, sex, heart failure, exam setting, and left ventricular 
volumetric indices. Analyses of patients with heart failure included medications as well as left 
ventricular volume and wall thicknesses. All analyses were performed using R (version 3.4.3) and 
the survival package.(18) Hypothesis tests were two-tailed and used a 0.05 level of significance. 
 
RESULTS 
Study Population 
596,503 echocardiograms from 271,201 patients were identified between 1998 and 2018.  
14,155 echocardiograms were excluded due to missing or invalid date of death (n=608), sex 
(n=200), height, weight or BMI (n=13,347). Physician-reported LVEF was missing for 
178,371 echocardiograms; these patients had a lower prevalence of most diagnoses and had a 
lower risk of mortality compared to patients with a reported LVEF (Table S2). Finally, 
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403,977 echocardiograms from 203,135 unique patients met the inclusion criteria (Table 1, Table 
S3). The mean age was 64 years; 52% were men; 13% had a diagnosis of heart failure. The most 
commonly reported LVEF categories were 55-60% (34%) and 60-65% (26%).  Chest pain 
(15.4%), dyspnea / fatigue (12.7%), coronary artery disease (10.3%), aortic valve disease (9.2%), 
and congestive heart failure (7.9%) were the top 5 indications for echocardiography (Table S4). 
Sepsis, bacteremia, and endocarditis together comprised 2.2%; shock and hypotension each 
comprised 0.3% of indications. The indication was unknown in 8.8%; a large number of 
uncommon indications (each <0.1%) together accounted for 7.6% of echocardiograms.  
In the New Zealand dataset, 45,531 echocardiograms from 35,976 patients were acquired 
between 2008–2017. The mean age was 63 years (SD, 17). Death occurred in 4,781 patients 
(13.3%) who had 6,375 echocardiograms (14.8%). The median follow-up time based on the 
reverse Kaplan-Meier method was 3.2 years (IQR, 1.9 – 4.7). 
All-Cause Mortality 
46,258 (23%) patients, who had undergone 108,578 (27%) echocardiograms, died. The median 
follow-up duration was 4.0 years (IQR, 1.3-8.4), and 50% of echocardiograms had at least 5.2 
years of follow-up until censoring or were followed until death. Adjusted LVEF hazard ratios 
showed a u-shaped relationship with a nadir at 60-65%; all other LVEF intervals had significantly 
higher hazard ratios (Figure 1A). The adjusted hazard ratio for LVEF ≥70% was significantly 
increased (1.71 [95% CI, 1.64-1.77]) and similar to that for LVEF 35-40% 
(1.73, [95% CI, 1.66-1.80]). Patients with an LVEF of 55-60% and 65-70% LVEF also had 
significantly higher mortality (1.06 [95% CI, 1.04-1.08] and 1.17 [95% CI, 1.14-1.20], respectively. 
Unadjusted Kaplan-Meier estimators illustrated the stratification of survival by LVEF (Figure 1B). 
Similar results, including a nadir at LVEF of 60-65%, were seen in the unadjusted hazard ratios 
in the validation dataset (Figure S1). 
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Older patients and those with diabetes, atrial fibrillation, chronic kidney disease, heart failure, and 
positive smoking history had higher adjusted hazard ratios (Figure 2). BMI adjusted hazard ratios 
had a u-shaped relationship with a nadir at 30-35 kg/m2, consistent with the “obesity paradox” 
identified in other studies. (19,20) 
Sensitivity Analyses 
When using only the first echocardiogram from each patient, the adjusted LVEF hazard ratios 
maintained a u-shaped relationship with a nadir at 60-65% (Figure S2; baseline characteristics, 
Table S5). Upon excluding echocardiograms with indeterminate LVEF plus those performed on 
patients less than 18 years of age or with congenital heart or great vessel defects, the adjusted 
LVEF hazard ratios were nearly unchanged (Figure S3). Using only echocardiograms with at least 
90 days of follow-up, thereby excluding early deaths from serious acute illness, the adjusted 
hazard ratios for the 65-70% and ≥70% LVEF intervals remained significantly elevated at 
1.14 (95% CI, 1.10-1.17) and 1.47 (95% CI, 1.41-1.54), respectively (Figure S4). A significant u-
shaped relationship was present for both inpatients and outpatients with nadirs at LVEF of 60-
65% (Figure S5). 
Analysis with Additional Entities Associated with Pathologically Elevated LVEF 
In the subgroup with a more detailed echocardiographic report including wall thickness, volumes 
and mitral regurgitation severity, the adjusted hazard ratios for LVEF of 65-70% and ≥70% 
remained significantly elevated at 1.09 (95% CI, 1.05-1.12) and 1.26 (95% CI, 1.21-1.33), 
respectively (Figure S6). Increasing septal and posterior wall thicknesses, heart rate, anemia, 
mitral regurgitation, and inpatient investigation were all associated with increased adjusted hazard 
ratios. 
In this exploratory subgroup, the interaction (P<0.001) between LVEF and left ventricular end 
systolic volume indexed to body surface area (ESVi) demonstrated that larger volumes and 
9 
 
reduced LVEFs had higher adjusted hazard ratios (Figure S7). However, small ESVi (<10 ml/m2) 
also had higher adjusted hazard ratios. Similar results (Figure S8) were found for the interaction 
between LVEF and left ventricular end diastolic volume index (EDVi). For all but a few volume 
intervals with low sample sizes, the adjusted hazard ratios for the 65-70% and ≥70% LVEF 
intervals remained significantly elevated compared to LVEF of 60-65%. 
Analysis with Interactions between Age, Sex, and LVEF 
The relationship between LVEF and survival remained u-shaped for all age-groups and both 
sexes with nadirs at 60-65% (Figure 3). The significant interaction (P<0.001) amongst age, sex, 
and LVEF reflects both the differences in the slopes of the log-scale adjusted hazard ratio curves 
among the age-groups and the increased risk for men when LVEF was >55% but not for lower 
LVEFs. Furthermore, deviations from LVEF of 60-65% generally carried a greater multiplicative 
increase in risk for younger compared to older patients. 
Analysis in Patients with Heart Failure 
Characteristics of patients with heart failure are shown in Table S6. The relationship between 
LVEF and survival remained u-shaped for both inpatients and outpatients (Figure 4). Inpatients 
had higher adjusted hazard ratios compared to outpatients. For inpatients, the nadir was at LVEF 
60-65%. For outpatients, the nadir was at 55-60%. When a further adjustment was made for 
plasma concentrations of NT-proBNP in the subgroup that had such data, the strength and u-
shaped relationship between LVEF and mortality appeared blunted for outpatients at both low 
and high LVEF and for inpatients particularly at low LVEF, although the reduced sample size and 
subsequently wider confidence intervals increased uncertainty for this observation (Figure S9). 
 
DISCUSSION 
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We believe this is the first analysis exploring the relationship between mortality and routinely 
reported echocardiographic LVEF, the result that clinicians rely on most to make decisions. 
Values of 60-65% were associated with the lowest mortality while both lower and higher LVEF 
had higher mortality as indicated by significantly higher adjusted hazard ratios. This result was 
reproduced in an independent dataset from New Zealand. Deviation from this range was 
associated with an increase in mortality even after adjusting for numerous confounders. The 
13,563 patients in our study with LVEF ≥70% had a similar mortality rate as the 10,595 patients 
with an LVEF of 35-40%, which could not be entirely accounted for by differences in heart rate, 
blood pressure, left ventricular volume, wall thickness, mitral regurgitation, anemia or 
hyperthyroidism. Among patients with heart failure, similar u-shaped relationships between 
mortality and LVEF were found, suggesting that it may be inappropriate to pool all patients with 
preserved LVEF into a single group. 
An increase in mortality for LVEF ≥65% was observed across all age groups and both sexes. The 
trend persisted after removing echocardiograms with short follow-up to exclude deaths that may 
have been associated with acute illnesses such as sepsis or hypovolemia and after adjustment 
for other pathologies that might increase LVEF, such as mitral regurgitation, hypertrophy, anemia, 
and hyperthyroidism.(21–23) It has become common practice to define “preserved” as an LVEF 
>50% or >55%, but few studies have considered the implications of LVEF ≥65%. The nadir of the 
hazard ratio for incident heart failure was close to 60% in the MESA study.(12) In the GRACE 
registry, women with acute coronary events and LVEF>65% had higher rates of cardiac arrest or 
ventricular fibrillation and mortality compared to those with LVEF of 55-65%.(24) U-shaped 
relationships between unadjusted mortality and LVEF were observed for both chronic and acute 
heart failure.(7,25)  The present study provides further support to the evidence that an LVEF 
≥65% is associated with an increase in mortality. 
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For patients with heart failure, prior results have demonstrated little difference in mortality once 
LVEF exceeds 45%.(2) In the present study, LVEF≥70% predicted a higher mortality amongst 
both inpatients and outpatients with heart failure, as well as in the larger population without a 
diagnosis of heart failure, even after adjusting for many confounders, suggesting that these 
observations are unlikely to be spurious. Moreover, heart failure may be under-diagnosed in 
patients with a supra-normal LVEF as this is not currently a clinically-recognized entity. The 
strength of the u-shaped relationships was blunted at both low and high LVEF after adjusting for 
plasma concentrations of NT-proBNP, particularly amongst outpatients. Regardless of LVEF, 
plasma NT-proBNP is usually elevated in patients with chronic heart failure regardless of LVEF, 
confirming cardiac dysfunction and predicting outcome. However, NT-proBNP is a much weaker 
predictor of outcome in the acute setting, even though plasma concentrations are often very high 
and patient outcomes are poor.(26) Adjusting for a strong prognostic marker, such as NT-proBNP 
in the outpatient setting, would be expected to attenuate the relationship between LVEF and 
outcome. However, amongst inpatients, where it is a much weaker predictor, NT-proBNP should 
have little impact on the relationship between LVEF and mortality, which is what we observed. 
Clearly more research is needed to investigate these findings further. 
The limited accuracy and reproducibility of LVEF measurements leading to potential 
misclassification are well-known. Undoubtedly, such measurement errors occurred in our analysis 
and may have contributed to the narrow range of the risk-nadir. For example, when the reported 
LVEF is 55-60%, rather than 60-65%, more patients will have a true LVEF of <50% due to 
measurement error, which may contribute to higher risk. A similar effect may operate for a 
reported LVEF of 65-70%. Indeed, misclassification concerns were a major reason for recent 
guidelines recommending the introduction of an intermediate LVEF phenotype (HFmrEF; LVEF 
40-49%) as a “zone of uncertainty” between heart failure with reduced LVEF (HFrEF; LVEF <40%) 
and heart failure with preserved LVEF (HFpEF; LVEF ≥50%).(27) This zone reduces the chances 
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of misclassification and appears to be delivering important, clinically-relevant insights. 
Mineralocorticoid receptor antagonists (TOPCAT), angiotensin receptor blockers, (CHARM)(28) 
and beta-blockers(29) appear similarly effective for patients with HFrEF and HFmrEF but not 
when LVEF exceeds 50%, although there is a paucity of data on beta-blockers in HFpEF. The 
similar efficacy of interventions between HFrEF and HFmrEF could either be because of 
misclassification between these two phenotypes or simply because choosing <40% to define 
HFrEF was wrong; perhaps it should always have been <50%. However, our analyses suggest 
that risk for mortality increases even when LVEF is <60%. Given the inaccuracy of measuring 
LVEF for an individual patient, it may be fruitless to further refine the limit. However, this analysis 
suggests that a fourth left ventricular phenotype, heart failure with supra-normal LVEF (HFsnEF), 
might one day be recognized. 
Limitations 
There is inherent imprecision in the clinical assessment of LVEF. However, clinically-assessed 
LVEF, rather than LVEF measured under controlled research conditions, is the actual 
measurement used to guide patient care, and information on its relationship with outcomes is 
lacking. Selection-bias could have affected our observations, although to a much smaller extent 
than in a clinical trial or conventional registry, because only patients who had a clinical indication 
for echocardiography were included. The results of the present study are applicable to the large 
heterogeneous patient population referred for echocardiography. Many echocardiograms were 
excluded due to missing physician-reported LVEF. While these patients had fewer comorbidities, 
similar BMI, and a lower mortality, it remains possible that they had impaired echo views or were 
otherwise missing LVEF for unknown reasons. 
Results from New Zealand did not include adjustment for confounders because these data were 
incomplete. While the unadjusted results (Figure S1) demonstrated strong similarities to the 
13 
 
unadjusted data in the primary dataset, this limitation prevented additional sensitivity analyses 
similar to those performed in the primary dataset. 
The study did not include advanced techniques such as 3D echocardiography, which, for 
example, has been recommended for evaluating valvular disease when considering surgical 
intervention,(30) or cardiac magnetic resonance imaging (MRI), which may provide greater 
accuracy compared to standard 2D echocardiography. However, 2D echocardiography is the 
most widely used modality for assessing cardiac function. Moreover, echocardiography has been 
performed on a large scale for decades, and the existing datasets are orders of magnitude larger 
than 3D echocardiography or cardiac MRI datasets. 
Potentially important confounders such as clinical status and the precise indication for 
echocardiography were not directly included due to either difficulty in defining an objective 
measure of clinical status or to the large number of specific indications which preclude adequately 
powered statistical analysis. The analysis with mortality censored in the first 3 months indirectly 
accounted for serious acute clinical status and revealed a similar u-shaped relationship and only 
modest decreases in the hazard ratios for those with an LVEF of 65-70% or ≥70%, indicating that 
early mortality from serious acute illness may explain a small portion, but not all, of the mortality 
associated with a high LVEF. Some confounders that may be pertinent to heart failure, such as 
cardiac resynchronization therapy, were not reliably recorded and were not included. 
Due to the study’s retrospective design and regression analyses, causation cannot be inferred 
between predictors and outcomes. Some predictors were based on diagnoses in problem lists, 
which may contain errors, however the large sample size reduces the impact of uncertainty due 
to random errors.  
14 
 
Cause of death was not adjudicated in the 46,258 deaths as it would require careful chart review. 
The Geisinger echocardiography population was largely of European ancestry (98%), as was the 
New Zealand population, which limits applicability to other races and ethnicities. 
Conclusion 
This analysis of a large dataset found that the relationship between survival and LVEF assessed 
by echocardiography in routine clinical practice is u-shaped. In general, patients with an LVEF of 
60-65% have the lowest risk of mortality regardless of age, sex, or other relevant confounders. 
Patients with LVEF ≥65% had a higher all-cause mortality. Whilst the present analyses were 
retrospective with all the inherent limitations described above, our results suggest that phenotypes 
of heart failure with a supra-normal LVEF (HFsnEF) might one day be recognized as a clinically 
relevant classification. 
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FIGURE CAPTIONS 
Figure 1. LVEF Hazard Ratios and Kaplan-Meier Survival Curves in the Primary Analysis (Number 
of Echocardiograms = 403,977). LVEF, left ventricular ejection fraction. LVEF intervals are inclusive of 
the lower threshold. (A) Error bars represent the 95% confidence interval. (B) Selected LVEF intervals are 
shown for clarity. The number at risk includes LVEF intervals not shown in the figure. 
 
Figure 2. Confounder Hazard Ratios in the Primary Analysis (Number of Echocardiograms = 
403,977). 
 
Figure 3. Analysis with Interactions between Age, Sex, and LVEF (Number of Echocardiograms = 
403,977). LVEF, left ventricular ejection fraction. LVEF intervals are inclusive of the lower threshold. The 
referent group was “female, under age 40 years, LVEF between 60-65%”. 
 
Figure 4. LVEF Adjusted Hazard Ratios in Patients with Heart Failure (Number of 
Echocardiograms = 40,616). LVEF, left ventricular ejection fraction. LVEF intervals are inclusive of the 
lower threshold. Error bars represent the 95% confidence interval. The referent group was “Outpatients 
with LVEF of 60-65%”. While 51,192 echocardiograms were performed on patients with heart failure in 
the primary analysis, only 40,616 echocardiograms are represented in Figure 4 due to excluding 
echocardiograms missing measurements of EDVi or wall thicknesses, for which adjustments were made 
in the analysis. 
